Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.

A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study ( 18 ), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.

also in 4,113 other papers

The estimated HR for individual cardiovascular events (supplemental Table 2, available in an online appendix), combined events (alternatives to the primary end point) (supplemental Table 3, available in an online appendix), or combined events for those patients achieving targeted blood glucose goals (supplemental Table 4, available in an online appendix) did not reach statistical significance.

also in 111,027 other papers